Fortis Group Advisors’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Fortis Group Advisors's AXSM Position: Q3 2026 in Review
Fortis Group Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 1,105 shares — an estimated $270K sold.
Fortis Group Advisors first reported a position in AXSM in Q4 2025 and held it in 3 quarters. The position peaked at $270K in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Fortis Group Advisors reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
- Fortis Group Advisors sold 1,105 Axsome Therapeutics shares in Q3 2026, an estimated $270K.
- Fortis Group Advisors first reported a position in Axsome Therapeutics in Q4 2025 and held it in 3 quarters.
- Fortis Group Advisors's Axsome Therapeutics position peaked at $270K in Q2 2026.
- 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Fortis Group Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.